Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring

AbbottAbbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has approved the company's next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The devices bring new benefits to patients with heart rhythm disorders, including a patient-preferred design without compromising battery longevity and MRI compatibility. In addition, the new devices offer Bluetooth technology and a new patient smartphone app for improved remote monitoring, allowing for increased patient/physician engagement and streamlined communications.

It is estimated that as many as 6.1 million people in the United States battle cardiac arrhythmias, or abnormal heart rhythms,(1) and ICDs are used to help reduce the risks of life-threatening arrhythmias. For patients with heart failure or in situations when the heart's chambers beat out of sync, CRT-Ds can be used to restore the heart's natural pattern of beating.

"We are focused on developing and delivering life-changing technologies that impact patient care in a meaningful way," said Randel Woodgrift, senior vice president, Cardiac Rhythm Management, Abbott. "The Gallant devices are the latest example of how Abbott is driving innovation to meet changing healthcare needs and helping to improve connectivity and engagement between patients and their doctors."

The new Gallant system pairs with Abbott's secure myMerlinPulse™, an iOS- and Android™- compatible mobile smartphone app that helps streamline communication between doctors and their patients. The app provides people with access to data, device performance, and transmission history, which helps them take an active role in their healthcare. Through the myMerlinPulse app, physicians can continuously monitor their patients remotely allowing for identification of asymptomatic episodes as well as patient-triggered transmissions, which can lead to earlier intervention and reduce clinical burden.

"The ability for patients to stay connected to their doctors via their implanted device and a smartphone app has the potential to change how healthcare providers and patients communicate with each other," said Raffaele Corbisiero, M.D., FACC, director of electrophysiology and pacing at Deborah Heart and Lung Center, Browns Mills, N.J. "The FDA's approval of Abbott's Gallant devices enables doctors to provide a more collaborative approach to treatment plans and the increased bond between a patient and provider will lead to better outcomes for all."

The Gallant system received CE Mark for use across Europe earlier this year.

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

1. Centers for Disease Control and Prevent, Atrial Fibrillation. https://www.cdc.gov/heartdisease/atrial_fibrillation.htm. Accessed June 3, 2020.

Most Popular Now

IBM Watson Health Recognizes Top-Perform…

IBM (NYSE: IBM) Watson Health® announced its 2020 Fortune/IBM Watson Health 100 Top Hospitals list and 15 Top Health Systems award winners, naming the top-performing hospitals and health systems in...

Proposed Framework for Integrating Chatb…

While the technology for developing artificial intelligence-powered chatbots has existed for some time, a new viewpoint piece in JAMA lays out the clinical, ethical, and legal aspects that must be...

The New Tattoo: Drawing Electronics on S…

One day, people could monitor their own health conditions by simply picking up a pencil and drawing a bioelectronic device on their skin. In a new study, University of Missouri...

SARS-CoV-2 Antibody Test from Siemens He…

Public Health England, in partnership with the University of Oxford, recently conducted a head-to-head evaluation of four commercial immunoassay tests available in the UK and used for the detection of...

World's Smallest Imaging Device has Hear…

A team of researchers led by the University of Adelaide and University of Stuttgart has used 3D micro-printing to develop the world's smallest, flexible scope for looking inside blood vessels...

Online Tools can Improve Autism Diagnosi…

Online tools and assessments can help speed up diagnosis of autism spectrum disorder (ASD), the first comprehensive survey of research in the field has concluded. The survey showed that using internet-based...

Optimizing Neural Networks on a Brain-In…

Many computational properties are maximized when the dynamics of a network are at a "critical point", a state where systems can quickly change their overall characteristics in fundamental ways, transitioning...

Clinical-Grade Wearables Offer Continuou…

Although it might be tempting to rely on your fitness tracker to catch early signs of COVID-19, Northwestern University researchers caution that consumer wearables are not sophisticated enough to monitor...

New Machine Learning Method Allows Hospi…

To answer medical questions that can be applied to a wide patient population, machine learning models rely on large, diverse datasets from a variety of institutions. However, health systems and...

NHS Lanarkshire to Advance Scotland's Pa…

An early warning system that helps busy doctors, nurses and other healthcare professionals to quickly identify when patients are at risk of deterioration is to be deployed across hospitals and...

Social Media and Radiology - The Good, t…

Bradley Spieler, MD, Vice Chairman of Radiology Research at LSU Health New Orleans School of Medicine, is the lead author of a Radiology Research Alliance paper examining the usefulness of...